Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (242)	1/27/2003 11:32:46 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CPTS Is down more than 14% on volume of 390K (ahead of its daily average.) Its ESSURE product, designed to cause fallopian tubal occlusion, is inserted as an outpatient procedure and is less invasive and less costly than tubal ligation and is already being marketed in Australia, China, Canada and Europe. CPTS is planning to file a PMA application with the FDA and expects to receive approval in 2003 to begin marketing Essure in the USA. The insiders own more than 20% of the shares and institutions that hold more than 120% of the float have reportedly done significant buying lately.<g> The company has about $3.80 in cash/share and no significant LTD with a current ratio of more than 20, but has been burning its cash at an accelerated pace due to start-up manufacturing costs and higher sales, general, and administrative expenses related to the commercial introduction of Essure. The analyst's consensus "target" is more than $20 (about 3x its present level.<g>) While trading at the 6.87 level today it made a new 52wks. L <g> siliconinvestor.com The stock has been on a steady downtrend since its October H at the 16 level.<g> siliconinvestor.com It is too soon to think about buying this (or any other stocks at present.<g>), but is probably worth to keep an eye on it in case we may run into "better times" some time in the distant future.<g> Bernard